Inhibition of relapsing experimental autoimmune encephalomyelitis in Biozzi ABH mice using a mouse CD52-specific monoclonal antibody

Abstract

Multiple Sclerosis (MS) is a major neurodegenerative disease, which is believed to arise following autoimmune attack to the central nervous system. Immune therapies can inhibit the development of relapsing multiple sclerosis. One of the most-effective, approved-therapies is Lemtrada/Alemtuzumab, a humanised CD52-depleting monoclonal antibody (mAb), whose potential side-effect is the development of secondary autoimmunities following immune reconstitution. We have shown that it is possible to re-establish immune tolerance by T cell depletion using CD4-depleting mAb followed by intravenous antigen (Pryce et al.